 |
|
Effect of a 1-Week Treatment With 0.5% Topical Fluorouracil on Occurrence of Actinic Keratosis After Cryosurgery
A Randomized, Vehicle-Controlled Clinical Trial
Joseph Jorizzo, MD;
Jonathan Weiss, MD;
Katharine Furst;
Christine VandePol, MD;
Sharon F. Levy, MD
Arch Dermatol. 2004;140:813-816.
Background No long-term randomized controlled clinical trial has compared the efficacy of cryosurgery alone vs cryosurgery following fluorouracil applications for the treatment of actinic keratosis.
Objective To determine the 6-month outcome of a 1-week course of 0.5% fluorouracil followed by cryosurgery.
Design Prospective, multicenter, randomized, double-blind, vehicle-controlled clinical trial performed in community and academic outpatient clinics.
Patients A total of 144 patients with 5 or more visible or palpable actinic keratoses on the face.
Interventions Topical 0.5% fluorouracil or vehicle once daily for 7 days. At the 4-week follow-up visit, residual lesions were treated with cryosurgery.
Main Outcome Measure Reduction in facial actinic keratoses from baseline to 4 weeks and 6 months.
Results At 4 weeks, mean actinic keratosis lesion count was reduced by 62.4% in the 0.5% fluorouracil group vs 28.8% in the vehicle group (P<.001), and complete clearance was achieved in 16.7% of patients in the 0.5% fluorouracil group vs 0% of those in the vehicle group (P<.001). At 6 months, mean lesion count was reduced by 67.0% in the 0.5% fluorouracil plus cryosurgery group vs 45.6% in the vehicle plus cryosurgery group (P = .01), and significantly more patients in the 0.5% fluorouracil plus cryosurgery group than in the vehicle plus cryosurgery group had complete clearance (30% vs 7.7%; P<.001).
Conclusions A 1-week course of topical 0.5% fluorouracil before cryosurgery is significantly more effective in reducing patients' numbers of actinic keratosis lesions 6 months after treatment than cryosurgery alone. The high occurrence rate of actinic keratosis lesions at 6 months suggests a need for follow-up.
From the Wake Forest University School of Medicine, Winston-Salem, NC (Dr Jorizzo); Gwinnett Clinical Research Center, Snellville, Ga (Dr Weiss); and Dermik Laboratories, Berwyn, Pa (Drs VandePol and Levy and Ms Furst). Dr Jorizzo is an occasional speaker for Dermik Laboratories, a subsidiary of Aventis Pharmaceuticals, and Dr Weiss has received research grants from Dermik Laboratories and Aventis Pharmaceuticals.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
5-Fluorouracil and Liquid Nitrogen Combo for Actinic Keratoses
Journal Watch Dermatology 2004;2004:3-3.
FULL TEXT
|
